EXEL designs next-generation medicines and regimens to battle cancer. Its drug discovery and development result in a product portfolio that attacks an expanding range of tumors. The company’s lead drug, Cabometyx, is a leading treatment of renal cell carcinoma. Also, the firm’s partnerships have expanded its care capabilities and financial strength.

EXEL’s second quarter saw earnings and sales beats as well as solid pipeline progress. Per-share earnings of $0.84 beat consensus expectations, and net revenues of $637.2 million showed 35.6% year-over-year increase driven by higher license revenues. Prescriptions volume grew 6% year-over-year as well.

It’s no wonder EXEL shares are up 10% this year – and they could rise more. MAPsignals data shows how Big Money investors are betting heavily on the forward picture of the stock.

Exelixis Shares Under Accumulation

Institutional volumes reveal plenty. Recently, EXEL has enjoyed strong investor demand, which we believe to be institutional support.

Each green bar signals unusually large volumes in EXEL shares. They reflect our proprietary inflow signal, pushing the stock higher:

Source: www.mapsignals.com

Plenty of health care names are under accumulation right now. But there’s a powerful fundamental story happening with Exelixis.

Exelixis Fundamental Analysis

Institutional support and a healthy fundamental backdrop make this company worth investigating. As you can see, EXEL has had strong sales and earnings growth:

  • 3-year sales growth rate (+23.7%)
  • 3-year earnings growth rate (+31.6%)

Source: FactSet

Now it makes sense why the stock has been powering to new heights. EXEL has a track record of strong financial performance.

Marrying great fundamentals with our proprietary software has found some big winning stocks over the long term.

Exelixis has been a top-rated stock at MAPsignals for years. That means the stock has unusual buy pressure and growing fundamentals. We have a ranking process that showcases stocks like this on a weekly basis.

It’s made the rare Top 20 report multiple times in the last year. The blue bars below show when EXEL was a top pick…rising along the way:

Source: www.mapsignals.com

Tracking unusual volumes reveals the power of money flows.

This is a trait that most outlier stocks exhibit…the best of the best. Big Money demand drives stocks upward.

Exelixis Price Prediction

The EXEL rally isn’t new at all. Big Money buying in the shares is signaling to take notice. Given the historical gains in share price and strong fundamentals, this stock could be worth a spot in a diversified portfolio.

Disclosure: the author holds no position in EXEL at the time of publication.

If you are a Registered Investment Advisor (RIA) or are a serious investor, take your investing to the next level, learn more about the MAPsignals process here.